Close

After-Hours Stock Movers 10/05: (SCYX) (ZUMZ) (JD) Higher; (ALNY) (IDRA) (MDCO) Lower (more...)

Go back to After-Hours Stock Movers 10/05: (SCYX) (ZUMZ) (JD) Higher; (ALNY) (IDRA) (MDCO) Lower (more...)

Jefferies Reiterates Hold on Yum! Brands (YUM) Following 3Q Report

October 7, 2016 8:06 AM EDT

Jefferies reiterated a Hold rating and $85.00 price target on Yum! Brands (NYSE: YUM) following the company's 3Q earnings report. YUM reported EPS of $1.09, slightly below the $1.10 consensus estimate. TB and KFC put up good results with 3% sss/9% oper profit growth and +4% sss and 11% oper profit... More

Oppenheimer Reiterates Outperform on Yum! Brands (YUM) Following 3Q Report

October 6, 2016 10:13 AM EDT

Oppenheimer reiterated an Outperform rating and $97.00 price target on Yum! Brands (NYSE: YUM) following the company's 3Q earnings report. Adjusted EPS was $1.09, compared to the Street's $1.10 estimate, as operating profits grew 11% globally. Comps at KFC (+4%) and TB (+3%) displayed a surprising beat and are outperforming... More

Stifel Raises Price Target on Zumiez, Inc. (ZUMZ) to $18 Following Comp Sales Report

October 6, 2016 10:04 AM EDT

Stifel reiterated a Hold rating on Zumiez, Inc. (NASDAQ: ZUMZ), and raised the price target to $18.00 (from $17.00), following the company's September comparable sales report. Comp sales increased 6.3%, better than the consensus estimate of 2%. Management provided an improved outlook for 3Q, given the... More

Wedbush Raises Price Target on Zumiez, Inc. (ZUMZ) to $18; Reiterates Neutral

October 6, 2016 7:58 AM EDT

Wedbush reiterated a Neutral rating on Zumiez, Inc. (NASDAQ: ZUMZ), and raised the price target to $18.00 (from $15.00), as September sales come in better than expected. ZUMZ reported sales up 6.3% versus consensus expectations for a 1% decline. Positive sales were driven by mens, accessories, and juniors. 3Q sales were guided up to $216- $217 million up from $209-$213 million (versus consensus of... More

BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure

October 6, 2016 6:29 AM EDT

BMO Capital upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Market Perform to Outperform with a price target of $48.00 (from $42.00), saying the company could benefit from Alnylam (NASDAQ: ALNY) discontinuation of the Revusiran program fter observing an imbalance of... More